Biotheranostics Launches Not Another Minute Campaign for its Breast Cancer Index® Test
December 11, 2019 08:00 ET
|
Biotheranostics, Inc.
San Diego, CA, Dec. 11, 2019 (GLOBE NEWSWIRE) -- Biotheranostics, Inc., announces the launch of its Not Another Minute campaign, revealing how Breast Cancer Index (BCI) is changing the game for...
Cascadian Therapeutics Amends HER2CLIMB Phase 2 Trial of Tucatinib in Metastatic HER2-Positive Breast Cancer to Support Registration
December 07, 2016 07:00 ET
|
Cascadian Therapeutics, Inc.
Updated Data from Phase 1b Triplet Combination Trial at SABCS; Increased Median PFS to 7.8 Months and ORR to 61 Percent; Median Duration of Response (MDR) at 10 Months in Third-line Setting for...
OncoMed Presents Vantictumab Biomarker Data at the San Antonio Breast Cancer Symposium (SABCS)
December 11, 2015 08:30 ET
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Dec. 11, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) presented new data related to the development of a novel predictive biomarker for vantictumab...